Hydromorphon Dura

Hydromorphone, the active ingredient in Hydromorphon Dura, is an opioid analgesic presented as an oral formulation for oral use. It is indicated for management of severe acute pain, postoperative pain, and cancer‑related pain in adult patients.

GNH USA supplies Hydromorphon Dura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Hydromorphon Dura is an opioid analgesic used to treat pain conditions that involve the central nervous system.

Severe acute pain: provides rapid, potent analgesia for intense pain episodes. Postoperative pain: helps control pain following surgical procedures. Cancer pain: offers opioid analgesia for malignant disease‑related pain.

Hydromorphon Dura may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Constipation - Drowsiness or sedation - Dry mouth

Serious or Rare Side Effects: - Respiratory depression, potentially life‑threatening - Severe hypotension or cardiovascular collapse - Addiction, dependence, or abuse potential - Adrenal insufficiency - Seizures (rare)

Before prescribing Hydromorphon Dura, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

Assess pain severity before initiating: ensure opioid therapy is appropriate. Evaluate respiratory function: monitor for depression, especially in patients with COPD or sleep apnea. Review concomitant CNS depressants: adjust dose or avoid combined use. Use the lowest effective dose: titrate carefully to balance analgesia and safety. Store at room temperature: keep in the original container, protect from moisture and light.

Hydromorphon Dura can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other opioids or strong CNS depressants (e.g., benzodiazepines, barbiturates) - Monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation - Alcohol or illicit substances that depress respiration

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole) - CYP3A4 inducers (e.g., rifampin, carbamazepine) - Serotonergic agents (risk of serotonin syndrome) - Antihistamines and certain antidepressants - Diuretics that may affect electrolyte balance